Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20143637 | 0.92 | PTPN1 (0.50) | PTPN1HDAC8NPSR1ACE | |
| SCHEMBL29727828 | 0.88 | NPSR1 (0.53) | PTPN1HDAC8NPSR1 | |
| SCHEMBL8233145 | 0.88 | NPSR1 (0.53) | PTPN1HDAC8NPSR1 | |
| SCHEMBL7228628 | 0.84 | ACE (0.59) | PTPN1HDAC8NPSR1ACE | |
| SCHEMBL7228636 | 0.84 | ACE (0.59) | PTPN1HDAC8NPSR1ACE | |
| SCHEMBL17486452 | 0.83 | PTPN1 (0.67) | PTPN1HDAC8 | |
| SCHEMBL3615808 | 0.81 | HDAC8 (0.49) | PTPN1HDAC8NPSR1ACE | |
| SCHEMBL6787776 | 0.80 | FKBP1A (0.49) | PTPN1 | |
| SCHEMBL204506 | 0.80 | FKBP1A (0.49) | PTPN1 | |
| SCHEMBL204505 | 0.80 | FKBP1A (0.49) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969709-B2 | Guanidinobenzoic acid ester compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | SERPINB1, REN, SPINT2 | PTPN1 662/4885HDAC8 1831/4885NPSR1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.